NCT05061277
Withdrawn
Phase 1
A PHASE 1, OPEN-LABEL, SINGLE SUBCUTANEOUS DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF LYOPHILIZED FORMULATION OF RECIFERCEPT IN HEALTHY CHINESE PARTICIPANTS
Overview
- Phase
- Phase 1
- Intervention
- Recifercept
- Conditions
- Healthy
- Sponsor
- Pfizer
- Locations
- 1
- Primary Endpoint
- Area Under the Serum Concentration Time Profile from Time Zero to 168 hrs (AUC0-168)
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the pharmacokinetic (PK), safety, tolerability and immunogenicity of a single subcutaneous (SC) dose of the lyophilized formulation of recifercept in healthy Chinese participants.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Chinese male and female participants of nonchildbearing potential must be 21 to 55 years of age, inclusive at the time of signing the ICD.
- •Chinese male and female participants who are overtly healthy as determined by medical evaluation.
- •Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- •Participants must be of Chinese ethnicity (individuals currently residing in mainland China who were born in China and have both parents of Chinese descent).
- •Body mass index (BMI) of 19.0 to 27.5 kg/m2; and a total body weight \>50 kg and ≤ 120 kg.
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
Exclusion Criteria
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Any condition possibly affecting drug absorption (eg, skin inflammation at infusion site, acne, rash, scarring, tattoos, erythema, sunburn, deep tanning, etc).
- •History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or serological reaction of syphilis. Prior hepatitis B vaccination is allowed.
- •Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the dose of study intervention.
- •Previous administration with an investigational drug/medical device within 30 days (or as determined by the local requirement) or 5 half lives preceding the dose of study intervention used in this study (whichever is longer).
- •A positive urine drug test.
- •Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. Pulse rate \> 100 beats/minute. Oral temperature (or ear temperature) \> 37.5 ℃.
- •Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval \>450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias).
- •Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
Arms & Interventions
Recifercept
A 300 mg single subcutaneous (SC) dose of recifercept for the treatment phase of study
Intervention: Recifercept
Outcomes
Primary Outcomes
Area Under the Serum Concentration Time Profile from Time Zero to 168 hrs (AUC0-168)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168 hours post-dose
Time for Cmax (Tmax)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Area Under the Serum Concentration Time Profile from Time 0 Extrapolated to Infinite Time (AUCinf)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Terminal Elimination Half-Life (t½)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Maximum Observed Concentration (Cmax)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Apparent Clearance (CL/F)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Apparent Volume of Distribution (Vz/F)
Time Frame: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Secondary Outcomes
- Incidence of Participants With Positive Neutralizing Antibodies (NAb)(Maybe 0, 168, 312, 504, 672 hours post-dose and maybe months 4 and/or month 7 post-dose)
- Incidence of Participants With Clinically Relevant Changes in 12-lead Electrocardiogram (ECG)(Baseline, within -3 hours pre-dose, and at 4, 24, 48, 72 hours post-dose, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Participants With Positive Anti-Drug Antibodies (ADA)(0, 168, 312, 504, 672 hours post-dose and maybe months 4 and/or month 7 post-dose)
- Incidence of Adverse Events (AEs)(Since inform consent form (ICD) is signed till up to about Day 29, or maybe till Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Participants With Clinically Relevant Changes in Vital Signs(Baseline, within -3 hours pre-dose, and at 4, 24, 48, 72 hours post-dose, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Participants With Infusion Site Reactions(From time of signing inform concent form (ICD) to approximately Day 29, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Clinical Laboratory Test Abnormalitiests(Baseline to approximately Day 22, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withwal from study)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study of M5049 in Healthy Japanese and Caucasian ParticipantsHealthyNCT04880213Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany36
Completed
Phase 1
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532Type 2 Diabetes MellitusHealthyNCT01369602Pfizer27
Active, not recruiting
Phase 1
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVHIV InfectionsNCT06652958ViiV Healthcare102
Completed
Phase 1
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BalcinrenoneHepatic ImpairmentNCT06388616AstraZeneca30
Completed
Phase 1
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersNASHNCT03207425Enanta Pharmaceuticals, Inc29